LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 5114

Search options

  1. Article ; Online: COVID-19 as the primary agent.

    Kawalec, Anna

    Social anthropology : the journal of the European Association of Social Anthropologists = Anthropologie sociale

    2020  Volume 28, Issue 2, Page(s) 295–296

    Keywords covid19
    Language English
    Publishing date 2020-05-18
    Publishing country England
    Document type Journal Article
    ZDB-ID 2001972-5
    ISSN 1469-8676 ; 0964-0282
    ISSN (online) 1469-8676
    ISSN 0964-0282
    DOI 10.1111/1469-8676.12867
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: COVID19 as the primary agent

    Kawalec, Anna

    Social Anthropology

    2020  Volume 28, Issue 2, Page(s) 295–296

    Keywords Arts and Humanities (miscellaneous) ; Sociology and Political Science ; Developmental and Educational Psychology ; Anthropology ; covid19
    Language English
    Publisher Wiley
    Publishing country us
    Document type Article ; Online
    ZDB-ID 2001972-5
    ISSN 1469-8676 ; 0964-0282
    ISSN (online) 1469-8676
    ISSN 0964-0282
    DOI 10.1111/1469-8676.12867
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  3. Article ; Online: The Cancer Nurse as Primary Palliative Care Agent During COVID-19.

    Rosa, William E / Finlayson, Catherine S / Ferrell, Betty R

    Cancer nursing

    2020  Volume 43, Issue 6, Page(s) 431–432

    Keywords covid19
    Language English
    Publishing date 2020-09-22
    Publishing country United States
    Document type Journal Article
    ZDB-ID 391995-x
    ISSN 1538-9804 ; 0162-220X
    ISSN (online) 1538-9804
    ISSN 0162-220X
    DOI 10.1097/NCC.0000000000000886
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: The Cancer Nurse as Primary Palliative Care Agent During COVID-19

    Rosa, William E. / Finlayson, Catherine S. / Ferrell, Betty R.

    Cancer Nursing

    2020  Volume 43, Issue 6, Page(s) 431–432

    Keywords Oncology(nursing) ; Oncology ; covid19
    Language English
    Publisher Ovid Technologies (Wolters Kluwer Health)
    Publishing country us
    Document type Article ; Online
    ZDB-ID 391995-x
    ISSN 1538-9804 ; 0162-220X
    ISSN (online) 1538-9804
    ISSN 0162-220X
    DOI 10.1097/ncc.0000000000000886
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  5. Article ; Online: Simnotrelvir as a potential treatment for COVID-19.

    McCarthy, Matthew W

    Expert opinion on pharmacotherapy

    2024  Volume 25, Issue 3, Page(s) 233–237

    Abstract: ... as a treatment for mild-to moderate COVID-19-were published, indicating the drug, when given in combination ... outpatients with mild-to-moderate COVID-19 are limited. The protease inhibitor nirmatrelvir in combination ... with ritonavir has proven effective in patients who are high risk for progression to severe COVID-19, but there ...

    Abstract Introduction: Simnotrelvir is a selective 3-chymotrypsin-like oral protease inhibitor with activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
    Areas covered: On 18 January 2024, results of a double-blind, randomized, placebo-controlled trial of simnotrelvir as a treatment for mild-to moderate COVID-19-were published, indicating the drug, when given in combination with ritonavir, shortened the time to resolution of symptoms.
    Expert opinion: Treatment options for most outpatients with mild-to-moderate COVID-19 are limited. The protease inhibitor nirmatrelvir in combination with ritonavir has proven effective in patients who are high risk for progression to severe COVID-19, but there are no approved therapies for standard-risk patients, who now comprise the majority of the population. Simnotrelvir appears to be effective in standard-risk patients, including those who have completed primary vaccination against COVID-19 and have received a booster dose. This manuscript examines the rationale for the development of simnotrelvir and explores how this drug may be used in the future to treat COVID-19.
    MeSH term(s) Humans ; COVID-19 Drug Treatment ; Antiviral Agents/therapeutic use ; Antiviral Agents/administration & dosage ; COVID-19 ; SARS-CoV-2 ; Ritonavir/therapeutic use ; Ritonavir/administration & dosage ; Protease Inhibitors/therapeutic use ; Randomized Controlled Trials as Topic ; Drug Therapy, Combination
    Chemical Substances Antiviral Agents ; Ritonavir (O3J8G9O825) ; Protease Inhibitors
    Language English
    Publishing date 2024-02-27
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2001535-5
    ISSN 1744-7666 ; 1465-6566
    ISSN (online) 1744-7666
    ISSN 1465-6566
    DOI 10.1080/14656566.2024.2323597
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Book ; Online: VACCELERATE Webinar (2 Talks): 1. National Cohort Study of Effectiveness and Safety of SARS-CoV-2/Covid-19 vaccines (ENFORCE) ; 2. Lessons from an international trial evaluating Vaccination Strategies for Recovered Inpatients with COVID-19 (VATICO)

    Reekie, Joanne / Mylonakis, Eleftherios

    2022  

    Abstract: ... against COVID-19 through conducting comprehensive high-throughput SARS-CoV-2 antibody analyses and ... Moderna) or BNT162b2 (Pfizer/BioNTech) at different timepoints after recovery. COVID-19 infection is known ... during the study specified period of deferral. COVID-19 infection is also thought to provide an adequate ...

    Title variant 1. ENFORCE Study; 2. VATICO Study
    Institution VACCELERATE
    Author's details with Dr Joanne Reekie, Rigshospitalet Copenhagen, DK; Dr Eleftherios Mylonakis, Brown University, USA ; Moderator: Nina Breinholt Stærke ; Organizer: VACCELERATE (Coordinator: Prof. Oliver A. Cornely)
    Abstract 1. The National cohort study of effectiveness and safety of SARS-CoV-2 vaccines (ENFORCE) is an equivalence trial to evaluate the effectiveness and safety of multiple new SARS-CoV-2 vaccines approved for use in the EU. The study is an open-labelled, non-randomized, parallel group, phase IV study with historical controls. The primary objective is to assess the effectiveness of vaccination. The study will compare and predict the durability of the minimal protective titre afforded by each of the vaccines against COVID-19 through conducting comprehensive high-throughput SARS-CoV-2 antibody analyses and in-depth characterization of the vaccine-induced cellular immune response. 2. The optimal timing and number of vaccinations against SARS-CoV-2 for recovered, unvaccinated inpatients that have participated in the ACTIV-3/TICO* population has not been determined yet. The subjects receive either one or two doses of mRNA-1273 (Moderna) or BNT162b2 (Pfizer/BioNTech) at different timepoints after recovery. COVID-19 infection is known to generally confer a period of SARS-CoV-2 immunity in most individuals, which would presumably be protective during the study specified period of deferral. COVID-19 infection is also thought to provide an adequate priming effect in most individuals, making the single vaccination arms that are part of this study a scientifically sound avenue for investigation. In this Phase 4, open-label trial, participants of the ACTIV-3/TICO clinical trial who received certain pre-specified blinded investigational agents or placebo as part of that trial, and who have since achieved sustained recovery, will be randomized in this 2x2 factorial design to one of four groups. *The ACTIV-3 Therapeutics for Inpatients with COVID-19 (TICO) study is trying to find new treatments for patients hospitalized with COVID-19.
    Keywords COVID-19
    Subject Coronavirus-Krankheit-2019 ; Corona virus disease 2019 ; Coronavirus disease 2019 ; 2019-nCoV acute respiratory disease ; Wuhan pneumonia ; COVID-19-Infektion ; Coronavirus-SARS-CoV-2-Infektion ; SARS-CoV-2-Infektion
    Subject code 610
    Language English
    Size 1 Online-Ressource (1 Videodatei, Lauflänge: 00:58:03)
    Publisher VACCELERATE
    Publishing place Cologe
    Publishing country Germany
    Document type Book ; Online
    HBZ-ID HT021398145
    DOI 10.4126/FRL01-006433910
    Database Repository for Life Sciences

    Kategorien

  7. Article ; Online: COVID-19 deaths on weekends.

    Manzoor, Fizza / Redelmeier, Donald A

    BMC public health

    2023  Volume 23, Issue 1, Page(s) 1596

    Abstract: ... France, Germany, Italy, Spain, Russia, India, Brazil, and Canada.: Results: The mean COVID-19 daily ... that reported deaths for COVID-19 might increase on weekends compared to weekdays.: Methods ... We collected data from the World Health Organization COVID-19 database. All deaths from March 7, 2020 to March 7 ...

    Abstract Background: Mortality statistics about daily deaths might change on weekends due to delays in reporting, uneven staffing, a different mix of personnel, or decreased efficiency. We hypothesized that reported deaths for COVID-19 might increase on weekends compared to weekdays.
    Methods: We collected data from the World Health Organization COVID-19 database. All deaths from March 7, 2020 to March 7, 2022 were included (two years). The primary analysis evaluated mean daily deaths on weekends compared to the preceding five workdays. Analyses were replicated in ten individual countries: United States, United Kingdom, France, Germany, Italy, Spain, Russia, India, Brazil, and Canada.
    Results: The mean COVID-19 daily deaths was higher on weekends compared to weekdays (8,532 vs. 8,083 p < 0.001), equal to a 6% relative increase (95% confidence interval 3% to 8%). The highest absolute increase was in the United States (1,483 vs. 1,220 deaths, p < 0.001). The second highest absolute increase was in Brazil (1,061 vs. 823 deaths, p < 0.001). The increase in deaths on weekends remained significant during the earlier and later months of the pandemic, as well as during the greater and lesser weeks of the pandemic.
    Conclusions: The apparent increased COVID-19 deaths reported on weekends might potentially reflect patient care, confound community trends, and affect the public perception of risk.
    MeSH term(s) Humans ; COVID-19 ; Brazil/epidemiology ; Canada ; Databases, Factual ; France
    Language English
    Publishing date 2023-08-22
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2041338-5
    ISSN 1471-2458 ; 1471-2458
    ISSN (online) 1471-2458
    ISSN 1471-2458
    DOI 10.1186/s12889-023-16451-8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Growing Evidence for Potential Use of Antidepressants for Long COVID.

    Rivas-Vazquez, Rafael A / Carrazana, Enrique J / Rivas-Vazquez, Emma V / Quintana, Alan

    The primary care companion for CNS disorders

    2024  Volume 26, Issue 3

    MeSH term(s) Humans ; Antidepressive Agents/therapeutic use ; COVID-19 ; Post-Acute COVID-19 Syndrome
    Language English
    Publishing date 2024-05-16
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2675414-9
    ISSN 2155-7780 ; 2155-7780
    ISSN (online) 2155-7780
    ISSN 2155-7780
    DOI 10.4088/PCC.23lr03690
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top